Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Neurocrine Biosciences Inc. (NBIX)

NASDAQ: NBIX · Biological Products, (No Diagnostic Substances) · San Diego, CA

Our rating: Positive

Positive reaffirmed at $164.85, moderate conviction, November 3, 2026.

Breaks if: The Positive view breaks if revenue growth in either of the next two reported periods comes in below 12% — a sharp enough deceleration to signal the core franchise is losing commercial altitude rather than maturing gracefully — or if trailing twelve-month free cash flow falls below $550M, indicating that cash conversion quality has deteriorated rather than held its current level. Either condition observed within the next twelve months would move the view to Neutral. On the upside, a second product reaching $300M or more in reported annual revenues with an independent patent runway would be the clearest evidence to revisit the case for Conviction.

Key figures

Market value$15.2B
Revenue, last 12 months$3.7B
Net income, last 12 months$703M
Free cash flow, last 12 months$1.0B
Price to earnings21.7×
Free cash flow yield6.8%
Dividend yield0.0%
Operating margin24.0%
Return on equity20.4%
Beta to the S&P 5000.77
Volatility, annualized36.8%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$1.1B41.2%$1.96$384M
June 30, 2026$959M39.5%$1.39$129M
March 31, 2026$815M42.2%$1.91$137M
December 31, 2025$806M28.3%$1.48$391M
September 30, 2025$795M27.8%$2.04$214M
June 30, 2025$688M16.5%$1.06$90M
March 31, 2025$573M11.1%$0.08$54M
December 31, 2024$628M21.8%$1.00$235M

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

16 ledger entries and 29 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.